Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1636 1656 1681 1683
This examiner grants 75% of resolved cases
Nancy J. Leith has resolved 830 cases in Art Unit 1600. The examiner has an allowance rate of 74.7 percent. This 74.7 percent rate is based on the 830 resolved cases in Tech Center 1600. Practitioners can use these figures to evaluate the probability of a grant. The volume of resolutions provides a specific data set for this examiner's history.
The interview lift is 44.0 percent. This 44.0 percent figure represents the change in the allowance rate when an interview is conducted. Practitioners should consider this lift when deciding on a prosecution strategy. This metric indicates how interviews correlate with the overall allowance rate. The 44.0 percent lift is a recorded factor in the examiner's prosecution profile.
The median time to allowance is 1108 days. This 1108 day duration is the middle value for the time from filing to grant. Applicants can use this figure to plan their prosecution timelines. The median pendency is a specific temporal measure in Art Unit 1600. It provides a benchmark for cases assigned to this examiner. Understanding this 1108 day timeline is important for managing expectations during the examination process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19174171 | ENGINEERED CIRCULARIZED pegRNAs AND USES THEREOF | Final Rejection | Trustees of Boston University |
| 17977788 | SYSTEM AND METHOD FOR HIGH-YIELD TRANSIENT EXPRESSION IN MAMMALIAN CELLS | Non-Final OA | LIFE TECHNOLOGIES CORPORATION |
| 18171578 | METHODS AND COMPOSITIONS FOR GENERATING A DELETION LIBRARY AND FOR IDENTIFYING A DEFECTIVE INTERFERING PARTICLE (DIP) | Non-Final OA | The Regents of the University of California |
| 17763110 | NOVEL RECEPTORS HAVING A HETEROLOGOUS STOP TRANSFER SEQUENCE FOR LIGAND-DEPENDENT TRANSCRIPTIONAL REGULATION | Non-Final OA | The Regents of the University of California |
| 17201347 | DELIVERY, USE AND THERAPEUTIC APPLICATIONS OF THE CRISPR-CAS SYSTEMS AND COMPOSITIONS FOR TARGETING DISORDERS AND DISEASES USING VIRAL COMPONENTS | Non-Final OA | President and Fellows of Harvard College |
| 18818523 | METHODS OF DETECTING ONCOGENIC FUSIONS AND USES THEREOF | Non-Final OA | Washington University |
| 17742503 | CRISPR-ASSOCIATED TRANSPOSASE SYSTEMS AND METHODS OF USE THEREOF | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 17742127 | NOVEL CRISPR ENZYMES AND SYSTEMS | Non-Final OA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 19272711 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 19272775 | METHODS AND COMPOSITIONS FOR MODULATING A GENOME | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 17608429 | MULTIPARTITE CRISPR DONOR | Non-Final OA | DSM IP Assets B.V. |
| 18283925 | NUCLEIC ACID DELIVERY TO THE CENTRAL NERVOUS SYSTEM | Non-Final OA | Biogen MA Inc. |
| 18272536 | Systems and Methods for Base Editing Of HBG1/2 Gene Promoter and Fetal Hemoglobin Induction | Non-Final OA | St. Jude Children's Research Hospital, Inc. |
| 18262420 | METHOD FOR PRODUCING TARGET DNA SEQUENCE AND CLONING VECTOR | Non-Final OA | NANJING GENSCRIPT BIOTECH CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy